|
Found 29 result(s) FROM 1963 pages containing the term 'cyclosporine'.
Wednesday Mar 25, 2009
Licorice Reduces Cyclosporine, Raises Methotrexate Levels
Licorice, often used in candies and food flavorings, significantly reduces absorption of cyclosporine, leading to lower than expected blood levels, but prolongs methotrexate clearance...
Tuesday Jul 15, 2008
Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...
Friday Feb 08, 2008
TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Monday Jan 07, 2008
Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...
Thursday Nov 01, 2007
Few Remissions From Switching to Other DMARDs After MTX Failure
If initial MTX fails to produce remission in RA, adding or switching to other conventional DMARDs is also unlikely to produce remissions...
Thursday Sep 13, 2007
Aspreva, Roche Terminate Lupus Nephritis Development Program; Previously Reported Phase III Data Does Not Adequately Support Regulatory Submission
Aspreva Pharmaceuticals Corp announced that Aspreva and Roche have decided not to proceed with a regulatory submission at this time for CellCept (oral mycophenolate mofetil, MMF) as an induction therapy for lupus nephritis...
Thursday Jul 19, 2007
Aspreva, Roche Report Preliminary Results for Phase III Study of CellCept in Lupus Nephritis; Fail to Achieve Primary Objective of Superiority to Intravenous Cyclophosphamide
Aspreva Pharmaceuticals Corp and Roche released preliminary results from a phase III clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) with intravenous cyclophosphamide (IVC), the current standard of care in patients suffering from lupus nephritis.
Tuesday Jul 03, 2007
Conventional Drugs Can Beat Back Early RA
Two-year data show that intensive treatment with methotrexate (MTX) and intra-articular corticosteroid can reduce X-ray progression in early RA...
Tuesday Jul 03, 2007
Twenty Percent of Pregnant Women With RA Conceived While Taking Potentially Fetotoxic Drugs
The growing use of combination regimens including methotrexate in early RA warrants increased attention to warning patients about potential risks during the first trimester of pregnancy…
Thursday Jun 14, 2007
Steroids Are DMARDS: MTX Plus Prednisolone Provides Durable Benefit in RA
Study confirms "window of opportunity" in early RA where steroids can reduce structural damage…
Tuesday Mar 13, 2007
Less Use of Diuretics, Earlier Hypouricemic Therapy Urged In Renal Transplant Patients At Risk for Recurrent Gout
Up to 23% of renal transplant recipients develop gout posttransplant but most are not getting hypouricemic therapy, even when they report recurrent gout attacks...
Tuesday Feb 06, 2007
Promising Results From Pilot Study of Tacrolimus for Lupus Nephritis
A test of tacrolimus in six lupus patients with persistent proteinuria despite the resolution of acute proliferative nephritis reports encouraging improvements in proteinuria and in hypoalbuminemia, particularly in patients with membranous lupus nephritis...
Monday Dec 11, 2006
Steroids, Cytotoxics Cause More Heart Damage than Biologics in Treating RA
Biologic immunosuppressive agents used to treat rheumatoid arthritis (RA) carry cardiovascular risks similar to that of methotrexate (MTX), but oral glucocorticoids and other cytotoxic RA drugs are more damaging to the heart...
Thursday Oct 12, 2006
Aspreva Achieves Targeted Patient Enrollment in Phase III Clinical Trial for CellCept In Lupus Nephritis
Aspreva Pharmaceuticals Corporation, an emerging pharmaceutical company focused on identifying, developing, and commercializing new indications for approved drugs and late-stage drug candidates for patients living with less common diseases, announced the completion of the targeted enrollment of 358 patients in its global 117-site phase III clinical trial for CellCept® (mycophenolate mofetil, F. Hoffmann-La Roche) in the treatment of lupus nephritis...
Friday Oct 06, 2006
Isotechnika's Calcineurin Inhibitor (ISA247) Receives Regulatory Green Light for Phase III Psoriasis Trials in Canada and Germany, Poland Is Pending
Isotechnika Inc., a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation, announced that it has received a No Objection Letter from Health Canada and similar approval from the German Competent Authority to conduct a pivotal phase III clinical trial of its lead immunosuppressive, oral calcineurin inhibitor drug candidate, ISA247 (an isomeric cyclosporine A analog mixture), for the treatment of moderate to severe psoriasis...
Friday Jun 09, 2006
Aspreva and Roche Granted Orphan Drug Designation for Mycophenolate Mofetil (Cellcept®) in Pemphigus Vulgaris
Aspreva Pharmaceuticals Corp announced that the US FDA has granted Orphan Drug designation for mycophenolate mofetil...
Monday May 22, 2006
MTX Plus Steroid Injection Into Joints Helps Control Early RA
Combining MTX with intraarticular steroids provides prompt control of early RA... Hetland ML, et al. Arthritis Rheum. 2006;54:1401-1409.
Monday Apr 03, 2006
Aspreva Pharmaceuticals Corporation Completes Patient Enrollment in Phase III Clinical Trial for Mycophenolate Mofetil (CellCeptR) in Patients With Pemphigus Vulgaris
Aspreva Pharmaceuticals Corporation, of Victoria, British Columbia, announced completion of patient enrollment in a global phase III clinical trial to evaluate mycophenolate mofetil (CellCept®)...
Monday Mar 06, 2006
Phase III Data for Centocor's Remicade® Show Rapid and Marked Improvement in Moderate to Severe Plaque Psoriasis
Centocor, Inc, of Horsham, Pennsylvania, announced the results from its phase III EXPRESS II study of Remicade® (infliximab)...
Wednesday Mar 01, 2006
CombinatoRx Drops Its Phase IIa Oral Product Candidate (CRx-140) for Psoriasis; Drug Candidate CRx-102 Demonstrates Positive Phase II Study Results in Hand Osteoarthritis
CombinatoRx Inc, of Boston, Massachusetts, announced the discontinuance of its phase IIa drug candidate, CRx-140...
Thursday Feb 16, 2006
Infliximab Effective Treatment for Refractory Childhood Uveitis
Tumor necrosis factor-alpha inhibition is effective for treatment of childhood uveitis refractory to standard immunosuppressive therapy... Saurenmann RK, et al. Rheumatology Advance Access. February 3, 2006.doi:10.1093/rheumatology/ke1030.
Wednesday Jan 25, 2006
Theramed Licenses Sigmasporin® (Cyclosporine) From EMS Sigma Pharma; Will Seek Approval to Market for RA and Psoriasis
Theramed Corporation, of Mississauga, Ontario, Canada, announced that it has entered into a licensing and distribution agreement with Nature's Plus...
Tuesday Nov 29, 2005
Aspreva Reports Success for CellCept® in Active Lupus Nephritis; Completes Enrollment in Phase III for Myasthenia Gravis
Aspreva Pharmaceuticals Corporation of Victoria, British Columbia, Canada, has announced the results of an investigator-initiated trial...
Monday Oct 17, 2005
Autoimmune Disease May Contribute to Increase in Non-Hodgkin's Lymphoma, Particularly Among Women
Providing further insight into the dramatic rise in the incidence of non-Hodgkin's lymphoma (NHL) over the last 20 years, a new study suggests that autoimmune diseases, as well as the potent immunosuppressive drugs commonly used for their treatment, may partly account for the increase in NHL, especially among women... Cuttner J, et al. J Rheumatol. 2005;32:1884-1887.
Wednesday Oct 12, 2005
Centocor Obtains Approval in Europe for Remicade® for Psoriasis
Centocor, Inc, and its marketing partner, Schering-Plough Corporation, have announced that the European Commission has granted approval of RemicadeR (infliximab)...
Monday Aug 29, 2005
Is There a Role for TNF Inhibitors in Refractory Subacute Cutaneous Lupus Erythematosus?
New research demonstrating expression of tumor necrosis factor-α (TNF-α) in refractory subacute cutaneous lupus erythematosus (SCLE) skin lesions suggests a possible role for TNF blockade in the treatment of this disease. Zampieri S, et al. Ann Rheum Dis. August 11, 2005. [Epub ahead of print]
Tuesday Aug 02, 2005
Etanercept Does Not Increase Risk of Squamous Cell Carcinoma in RA Patients
Unlike cyclosporine, etanercept does not appear to increase risk of skin cancer in rheumatoid arthritis (RA) patients... Lebwohl M, et al. Arch Dermatol. 2005;141:861-864.
Friday May 06, 2005
Use of DMARDs and Referral to Rheumatologists Too Low in Rheumatoid Arthritis Patients
A pre-biologic therapy era population study in British Columbia suggests that too few physicians are adhering to treatment guidelines for rheumatoid arthritis for early and aggressive intervention, delaying the "window of opportunity" when effective therapy can induce radiographic regression... Lacaille D, et al. Arthritis Rheum. 2005;53:241-248.
Thursday Oct 21, 2004
State-of-the-Art Lectures Reflect Pioneering Research in Rheumatology in the Past Year
The speakers highlighted new research in basic science, including genetic mechanisms at work in RA, and in clinical studies that further understanding of the efficacy of various therapeutic strategies…Barton A, et al. Arthritis Rheum. 2004.;50:1117-1121; Edwards JC, et al. N Engl J Med. 2004;350:2572-2581.
|
